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In 1988 Gabriel Kune of Melbourne published a seminal
paper reporting a negative association of the use of non-
steroidal anti-inflammatory drugs such as aspirin and
colorectal cancer. This prompted a deluge of case con-
trol and cohort studies, all but one of which confirmed
the finding. The conclusion of these observational stu-
dies was that regular aspirin users had half as many can-
cers. Four randomised controlled trials (RCTs) using
adenoma prevention as their endpoint gave a more
mixed result but meta-analysis supported benefit though
at a more modest level. Rothwell and colleagues
returned to the cancer registry to look up people who
took part in the early vascular disease prevention trials
using aspirin and found that about 7 years after starting
the trial, those who had been given aspirin started to
show a reduced cancer rate and a reduced cancer mor-
tality. The CAPP1 study recruited and followed 133 car-
riers of Familial Adenomatous Polyposis to test 600mg
aspirin and showed a weak effect on adenoma formation
and evidence of fewer large polyps. CAPP2 recruited
1009 carriers of Lynch syndrome resulting from a germ-
line defect in a mismatch repair gene, and tested 600mg
aspirin and/or 30g Novelose, a resistant starch, over
four years. Australia was a key contributor to this inter-
national trial. At the end of intervention phase there
was no difference in overall colorectal neoplasia in any
of the groups. Double blind post trial follow-up has
revealed a dramatic effect; at a mean of 5 years from
randomisation, those who had been taking the active
aspirin have significantly fewer colorectal cancers. Con-
fining analysis to the primary endpoint of colorectal
cancer after a minimum of 2 years on aspirin revealed
60% fewer cancers. A similar effect was evident when all
Lynch syndrome cancers were considered (paper in
press).
All people at risk of Lynch syndrome should be
advised to take aspirin and their physicians should take
usual measures to reduce the recognised burden of side
effects. This should include consideration of eradication
of H. pylori and use of a regular proton pump inhibitor
if there is evidence of gastric erosion. CAPP3 will com-
pare three different doses of enteric coated aspirin:
100mg, 300mg and 600mg in proven gene carriers
between 18 and 60 with treatment for a minimum of 5
years and unlimited follow-up. In our present state of
knowledge a pragmatic position is to recommend
immediate introduction of a low dose daily aspirin (75-
100mg) and encouragement to log on to the new
CAPP3 website to keep abreast of the emerging story.
This dose will not preclude joining the RCT in 2012
and will allow us to explore methods to personalise the
aspirin dose in future by assessment of the genetic basis
of aspirin sensitivity and resistance.
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